vs

Side-by-side financial comparison of GRACO INC (GGG) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

GRACO INC is the larger business by last-quarter revenue ($593.2M vs $321.1M, roughly 1.8× MADRIGAL PHARMACEUTICALS, INC.). GRACO INC runs the higher net margin — 22.3% vs -18.2%, a 40.6% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 8.1%). GRACO INC produced more free cash flow last quarter ($184.3M vs $-133.8M).

Graco Inc. is an American industrial company that specializes in the development and manufacturing of fluid-handling systems and products. The company is headquartered in Minneapolis, Minnesota, and markets its products to customers worldwide.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

GGG vs MDGL — Head-to-Head

Bigger by revenue
GGG
GGG
1.8× larger
GGG
$593.2M
$321.1M
MDGL
Growing faster (revenue YoY)
MDGL
MDGL
+202.7% gap
MDGL
210.8%
8.1%
GGG
Higher net margin
GGG
GGG
40.6% more per $
GGG
22.3%
-18.2%
MDGL
More free cash flow
GGG
GGG
$318.2M more FCF
GGG
$184.3M
$-133.8M
MDGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GGG
GGG
MDGL
MDGL
Revenue
$593.2M
$321.1M
Net Profit
$132.5M
$-58.6M
Gross Margin
51.7%
Operating Margin
26.7%
-18.6%
Net Margin
22.3%
-18.2%
Revenue YoY
8.1%
210.8%
Net Profit YoY
21.9%
1.4%
EPS (diluted)
$0.78
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GGG
GGG
MDGL
MDGL
Q4 25
$593.2M
$321.1M
Q3 25
$543.4M
$287.3M
Q2 25
$571.8M
$212.8M
Q1 25
$528.3M
$137.3M
Q4 24
$548.7M
$103.3M
Q3 24
$519.2M
$62.2M
Q2 24
$553.2M
Q1 24
$492.2M
$0
Net Profit
GGG
GGG
MDGL
MDGL
Q4 25
$132.5M
$-58.6M
Q3 25
$137.6M
$-114.2M
Q2 25
$127.6M
$-42.3M
Q1 25
$124.1M
$-73.2M
Q4 24
$108.7M
$-59.4M
Q3 24
$122.2M
$-107.0M
Q2 24
$133.0M
Q1 24
$122.2M
$-147.5M
Gross Margin
GGG
GGG
MDGL
MDGL
Q4 25
51.7%
Q3 25
53.2%
Q2 25
52.4%
Q1 25
52.6%
96.7%
Q4 24
50.9%
Q3 24
53.2%
Q2 24
54.4%
Q1 24
54.1%
Operating Margin
GGG
GGG
MDGL
MDGL
Q4 25
26.7%
-18.6%
Q3 25
30.3%
-39.7%
Q2 25
27.5%
-22.2%
Q1 25
27.3%
-57.8%
Q4 24
23.7%
-64.8%
Q3 24
28.1%
-187.1%
Q2 24
29.2%
Q1 24
27.0%
Net Margin
GGG
GGG
MDGL
MDGL
Q4 25
22.3%
-18.2%
Q3 25
25.3%
-39.8%
Q2 25
22.3%
-19.9%
Q1 25
23.5%
-53.4%
Q4 24
19.8%
-57.5%
Q3 24
23.5%
-172.0%
Q2 24
24.0%
Q1 24
24.8%
EPS (diluted)
GGG
GGG
MDGL
MDGL
Q4 25
$0.78
$-2.55
Q3 25
$0.82
$-5.08
Q2 25
$0.76
$-1.90
Q1 25
$0.72
$-3.32
Q4 24
$0.63
$-2.50
Q3 24
$0.71
$-4.92
Q2 24
$0.77
Q1 24
$0.71
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GGG
GGG
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$624.1M
$198.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$2.7B
$602.7M
Total Assets
$3.3B
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GGG
GGG
MDGL
MDGL
Q4 25
$624.1M
$198.7M
Q3 25
$618.7M
$295.7M
Q2 25
$534.9M
$186.2M
Q1 25
$536.1M
$183.6M
Q4 24
$675.3M
$100.0M
Q3 24
$764.5M
$232.7M
Q2 24
$666.0M
Q1 24
$622.7M
$622.5M
Total Debt
GGG
GGG
MDGL
MDGL
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Q1 24
$116.1M
Stockholders' Equity
GGG
GGG
MDGL
MDGL
Q4 25
$2.7B
$602.7M
Q3 25
$2.6B
$625.7M
Q2 25
$2.5B
$696.0M
Q1 25
$2.5B
$710.6M
Q4 24
$2.6B
$754.4M
Q3 24
$2.5B
$777.2M
Q2 24
$2.4B
Q1 24
$2.3B
$850.8M
Total Assets
GGG
GGG
MDGL
MDGL
Q4 25
$3.3B
$1.3B
Q3 25
$3.2B
$1.4B
Q2 25
$3.0B
$1.0B
Q1 25
$3.0B
$996.6M
Q4 24
$3.1B
$1.0B
Q3 24
$3.0B
$1.1B
Q2 24
$2.9B
Q1 24
$2.8B
$1.1B
Debt / Equity
GGG
GGG
MDGL
MDGL
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GGG
GGG
MDGL
MDGL
Operating Cash FlowLast quarter
$196.3M
$-133.5M
Free Cash FlowOCF − Capex
$184.3M
$-133.8M
FCF MarginFCF / Revenue
31.1%
-41.7%
Capex IntensityCapex / Revenue
2.0%
0.1%
Cash ConversionOCF / Net Profit
1.48×
TTM Free Cash FlowTrailing 4 quarters
$637.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GGG
GGG
MDGL
MDGL
Q4 25
$196.3M
$-133.5M
Q3 25
$179.2M
$79.8M
Q2 25
$182.7M
$-47.1M
Q1 25
$125.4M
$-88.9M
Q4 24
$185.2M
$-104.5M
Q3 24
$178.6M
$-67.0M
Q2 24
$139.0M
Q1 24
$118.9M
$-149.2M
Free Cash Flow
GGG
GGG
MDGL
MDGL
Q4 25
$184.3M
$-133.8M
Q3 25
$175.7M
$79.0M
Q2 25
$163.1M
Q1 25
$114.8M
Q4 24
$171.3M
$-104.7M
Q3 24
$159.2M
$-67.8M
Q2 24
$102.7M
Q1 24
$81.7M
$-149.5M
FCF Margin
GGG
GGG
MDGL
MDGL
Q4 25
31.1%
-41.7%
Q3 25
32.3%
27.5%
Q2 25
28.5%
Q1 25
21.7%
Q4 24
31.2%
-101.3%
Q3 24
30.7%
-109.0%
Q2 24
18.6%
Q1 24
16.6%
Capex Intensity
GGG
GGG
MDGL
MDGL
Q4 25
2.0%
0.1%
Q3 25
0.6%
0.3%
Q2 25
3.4%
0.0%
Q1 25
2.0%
0.0%
Q4 24
2.5%
0.2%
Q3 24
3.7%
1.3%
Q2 24
6.6%
Q1 24
7.6%
Cash Conversion
GGG
GGG
MDGL
MDGL
Q4 25
1.48×
Q3 25
1.30×
Q2 25
1.43×
Q1 25
1.01×
Q4 24
1.70×
Q3 24
1.46×
Q2 24
1.05×
Q1 24
0.97×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GGG
GGG

Industrial$284.3M48%
Contractor$265.5M45%
Other$43.4M7%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons